Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer

In patients with castration-resistant prostate cancer (CRPC), clinical resistances such as androgen receptor (AR) mutation, AR overexpression, and AR splice variants (ARVs) limit the effectiveness of second-generation antiandrogens (SGAs). Several strategies have been implemented to develop novel an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Meng, Zhang, Rongyu, Zhang, Zixiong, Zhang, Ning, Li, Chenfan, Xie, Yongli, Xia, Haoran, Huang, Fangjiao, Zhang, Ruoying, Liu, Ming, Li, Xiaoyu, Cen, Shan, Zhou, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901937/
https://www.ncbi.nlm.nih.gov/pubmed/36656639
http://dx.doi.org/10.7554/eLife.70700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901937/
https://www.ncbi.nlm.nih.gov/pubmed/36656639
http://dx.doi.org/10.7554/eLife.70700

Ejemplares similares